Beispiel: Heart Attack

Suchen Sie in klinischen Studien nach: Gossypol acetic acid

Insgesamt 25 ergebnisse

    • NCT00848016
      Abgeschlossen
      Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
      Bedingungen: Recurrent Adrenocortical Carcinoma; Stage III Adrenocortical Carcinoma; Stage IV Adrenocortical Carcinoma
    • NCT00540722
      Abgeschlossen
      Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
      Bedingungen: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    • NCT00773955
      Abgeschlossen
      R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
      Bedingungen: Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer
    • NCT00544596
      Abgeschlossen
      R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
      Bedingungen: Extensive Stage Small Cell Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    • NCT00666666
      Abgeschlossen
      R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
      Bedingungen: Adenocarcinoma of the Prostate; Stage IV Prostate Cancer
    • NCT01003769
      Beendet
      Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
      Bedingungen: Recurrent Chronic Lymphocytic Leukemia
    • NCT02697344
      Aktiv, nicht rekrutierend
      R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma
      Bedingungen: Recurrent Plasma Cell Myeloma
    • NCT00286793
      Abgeschlossen
      Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
      Bedingungen: Prostate Cancer
    • NCT00286780
      Abgeschlossen
      Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia
      Bedingungen: Chronic Lymphocytic Leukemia
    • NCT00561197
      Beendet
      An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
      Bedingungen: Locally Advanced Esophageal or GE Junction Cancer
    • NCT00988169
      Beendet
      Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
      Bedingungen: Lung Cancer
    • NCT01977209
      Unbekannter Status
      Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression
      Bedingungen: Non-small Cell Lung Cancer
    • NCT00934076
      Zurückgezogen
      Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer
      Bedingungen: Carcinoma, Non Small Cell Lung
    • NCT00275431
      Abgeschlossen
      Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
      Bedingungen: Follicular Lymphoma; Diffuse Large Cell Lymphoma; Mantle Cell Lymphoma; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia
    • NCT00286806
      Abgeschlossen
      A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
      Bedingungen: Hormone Refractory Prostate Cancer
    • NCT00891072
      Abgeschlossen
      Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
      Bedingungen: Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific; Waldenström Macroglobulinemia
    • NCT01285635
      Beendet
      A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck
      Bedingungen: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    • NCT00544960
      Abgeschlossen
      A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
      Bedingungen: Non-small Cell Lung Cancer
    • NCT00397293
      Abgeschlossen
      Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
      Bedingungen: Small Cell Lung Cancer
    • NCT00571675
      Abgeschlossen
      A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
      Bedingungen: Hormone Refractory Prostate Cancer
    • NCT01633541
      Aktiv, nicht rekrutierend
      Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
      Bedingungen: Laryngeal Cancer
    • NCT00440388
      Abgeschlossen
      Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
      Bedingungen: Follicular Lymphoma
    • NCT00390403
      Abgeschlossen
      Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
      Bedingungen: Brain and Central Nervous System Tumors
    • NCT04764448
      Rekrutierung
      A Study of Belcesiran in Patients With A1ATD-Associated Liver Disease
      Bedingungen: Alpha 1-Antitrypsin Deficiency
    • NCT00244374
      Abgeschlossen
      A Randomized Trial of Vaccine Adherence in Young Injection Drug Users
      Bedingungen: Medication Adherence; Substance Abuse, Intravenous; Risk Behavior; Hepatitis A; Hepatitis B; Hepatitis C
      Krankheiten
      Sponsoren und Mitarbeiter
      Drogeninterventionen
      Bedingungen
      Seltene Krankheiten
      Drogeninterventionen
      Nahrungsergänzungsmittel
      Sponsor / Mitarbeiter
      Standorte